M, Nishimura K., Watanabe Y., Kitamura T., Nagashima T., Tokoro T., Takatani N., Sato S., Yamazaki T., Hashimoto H., Kobayashi T., Ono Supplementary Material for: Possible Inhibitory Effect of Erythropoiesis-Stimulating Agents at the Predialysis Stage on Early-Phase Coronary Events after Hemodialysis Initiation <strong><em>Background:</em></strong> We examined whether the use of erythropoiesis-stimulating agents (ESAs) to correct anemia at the predialysis stage could inhibit early-phase coronary events after hemodialysis initiation. <b><i>Methods:</i></b> We enrolled 242 patients with chronic kidney disease who had received continued medical treatments and initiated maintenance hemodialysis from 1 September 2000 to 31 December 2014 at Toujinkai Hospital. Patients with a previous history of blood transfusion or any cardiovascular events or interventions were excluded. The coronary events were followed for 1 year after initiation of hemodialysis. <b><i>Results:</i></b> Coronary events occurred in 51 of 242 patients: 10 patients had acute coronary syndrome [9 with percutaneous coronary intervention (PCI), 1 without intervention], and 41 had elective coronary revascularization (38 PCI and 3 coronary artery bypass graft). ESA was administered in 118 of 242 patients (48.8%). In stepwise logistic analysis, coronary events were positively associated with nonuse of ESA at the predialysis stage (odds ratio 2.66, p = 0.005) and diabetes mellitus (odds ratio 5.33, p < 0.001). When dividing the patients into 4 subgroups by blood hemoglobin (Hb) level (8.5 g/dl) and the use/nonuse of ESA, coronary event-free survival rates were higher (p = 0.005) in those with Hb ≥8.5 g/dl, ESA+ (86.6%, n = 82) and tended to be higher (p = 0.055) in those with Hb <8.5 g/dl, ESA+ (86.1%, n = 36) than in patients with Hb <8.5 g/dl, ESA- (68.6%, n = 86) in a Kaplan-Meier analysis. <b><i>Conclusions:</i></b> The use of ESA to correct anemia at the predialysis stage may inhibit early-phase coronary events after hemodialysis initiation •Anemia;•Chronic kidney disease;•Coronary plaque;•Erythropoiesis-stimulating agent;•Hemodialysis 2016-08-11
    https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Possible_Inhibitory_Effect_of_Erythropoiesis-Stimulating_Agents_at_the_Predialysis_Stage_on_Early-Phase_Coronary_Events_after_Hemodialysis_Initiation/3571065
10.6084/m9.figshare.3571065.v1